William Blair Initiates Coverage on Immunic (NASDAQ:IMUX)

Research analysts at William Blair initiated coverage on shares of Immunic (NASDAQ:IMUX) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating on the stock. William Blair also issued estimates for Immunic’s FY2025 earnings at ($0.89) EPS.

A number of other brokerages have also weighed in on IMUX. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Immunic in a report on Friday, February 21st. Finally, D. Boral Capital reissued a “buy” rating and issued a $17.00 target price on shares of Immunic in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $12.67.

Immunic Stock Performance

IMUX opened at $1.20 on Tuesday. The stock has a market capitalization of $108.09 million, a PE ratio of -0.98 and a beta of 1.89. The stock’s 50 day moving average price is $1.07 and its 200-day moving average price is $1.21. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the last quarter. State Street Corp boosted its stake in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares in the last quarter. Jane Street Group LLC grew its position in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. Virtu Financial LLC bought a new stake in Immunic during the 3rd quarter valued at about $50,000. Finally, HB Wealth Management LLC purchased a new position in Immunic in the fourth quarter worth about $81,000. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.